<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3445">Dexmedetomidine (DEX) may spare other sedative use, reduce delirium incidence, facilitate earlier extubation, and thereby prevent the need for a tracheostomy as well as reduce hospital expenses. There is however a paucity of data in patients with cancer. We sought to evaluate the clinical and cost-effectiveness of the drug in this setting.</p>
